DIAGNOS Announces Short Term Financing
June 17 2019 - 2:54PM
Diagnos Inc. (“DIAGNOS” or “the Corporation”) (TSX Venture: ADK)
(OTCQB:DGNOF) a leader in early detection of critical health issues
through the use of its FLAIRE platform based on Artificial
Intelligence (AI), announces a financing of $250,000 in the form of
short term debt.
DIAGNOS and three arm’s length persons have
entered into three unsecured and non-convertible loan agreements
(the “Loans”), respectively for $125,000, $75,000 and $50,000. The
Corporation shall repay the principal of the Loans and any accrued
interest, at the annual rate of 6%, on, or before, December 17,
2019. As a bonus to the Loans, the Corporation is granting the
Lenders an aggregate number of 250,000 non-transferable share
purchase warrants (each a “Warrant”) enabling its holder to
purchase one common share of the Corporation per Warrant, at a
price of $0.35 per share, for a period of twelve months ending June
17, 2020 (each, a “Loan Bonus”).
The Loan proceeds will be used to fund the
operating expenses of the Corporation.
The Warrants and underlying common shares are
subject to a four-month hold period from the issuance date of the
Warrants. The Loan Bonuses remain subject to the final approval of
the TSX Venture Exchange. All monies quoted in this press release
were stated and paid in lawful money of Canada, unless otherwise
specified.
DIAGNOS is also announcing that its stock symbol
used on the OTCQB market has been changed from DGNOD to DGNOF.
About DIAGNOS
DIAGNOS is a publicly-traded Canadian
corporation with a mission of early detection of critical health
issues through the use of its Artificial Intelligence (“AI”) tool
CARA (Computer Assisted Retina Analysis). CARA is a
tele-ophthalmology platform that integrates with existing equipment
(hardware and software) and processes at the point of care. CARA’s
Artificial Intelligence image enhancement algorithms make standard
retinal images sharper, clearer and easier to read. CARA is
accessible securely over the internet, and is compatible with all
recognized image formats and brands of fundus cameras, and is EMR
compatible. CARA is a cost-effective tool for screening large
numbers of patients in real-time. CARA complies with local
regulations, is FDA cleared for commercialization in the United
States of America, is Health Canada licensed for commercialization
in Canada and is CE marking compliant in Europe.
Additional information is available at
www.diagnos.com and www.sedar.com
For further information, please contact:
Mr. André Larente, PresidentDIAGNOS IncTel:
450-678-8882 ext. 224alarente@diagnos.ca
This news release contains forward-looking
information. There can be no assurance that forward-looking
information will prove to be accurate, as actual results and future
events could differ materially from those anticipated in these
statements. DIAGNOS disclaims any intention or obligation to
publically update or revise any forward-looking information,
whether as a result of new information, future events or otherwise.
The forward-looking information contained in this news release is
expressly qualified by this cautionary statement.
Neither the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
Diagnos (TSXV:ADK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Diagnos (TSXV:ADK)
Historical Stock Chart
From Apr 2023 to Apr 2024